PortalPublikationenHealing of lymphocytic gastritis after Helicobacter pylori e...

Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial

Standard

Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. / Madisch, A; Miehlke, S; Neuber, F; Morgner, A; Kuhlisch, E; Rappel, S; Lehn, N; Bayerdörffer, E; Seitz, G; Stolte, M.

in: ALIMENT PHARM THER, Jahrgang 23, Nr. 4, 15.02.2006, S. 473-9.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Madisch, A, Miehlke, S, Neuber, F, Morgner, A, Kuhlisch, E, Rappel, S, Lehn, N, Bayerdörffer, E, Seitz, G & Stolte, M 2006, 'Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial', ALIMENT PHARM THER, Jg. 23, Nr. 4, S. 473-9. https://doi.org/10.1111/j.1365-2036.2006.02778.x

APA

Madisch, A., Miehlke, S., Neuber, F., Morgner, A., Kuhlisch, E., Rappel, S., Lehn, N., Bayerdörffer, E., Seitz, G., & Stolte, M. (2006). Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. ALIMENT PHARM THER, 23(4), 473-9. https://doi.org/10.1111/j.1365-2036.2006.02778.x

Vancouver

Madisch A, Miehlke S, Neuber F, Morgner A, Kuhlisch E, Rappel S et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. ALIMENT PHARM THER. 2006 Feb 15;23(4):473-9. https://doi.org/10.1111/j.1365-2036.2006.02778.x

Bibtex

@article{77576a7d2d834d8898cd5b23a8535024,
title = "Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial",
abstract = "BACKGROUND: An association between Helicobacter pylori infection and lymphocytic gastritis has been postulated.AIM: To assess the long-term effect of H. pylori eradication therapy on lymphocytic gastritis in a double-blind, placebo-controlled, multicentre trial.METHODS: Patients with lymphocytic gastritis were randomized to receive either 1-week triple therapy for eradication of H. pylori or omeprazole plus placebo. Endoscopy and histology was performed at baseline and after 3 and 12 months. Patients of the omeprazole/placebo group with persistent lymphocytic gastritis after 12 months received crossover open-label triple therapy.RESULTS: Fifty-one patients were randomized. Intention-to-treat analysis revealed a trend to a higher healing rate of lymphocytic gastritis 3 months after triple therapy compared with omeprazole/placebo (83.3% vs. 57.7%, 95% CI for RR: 0.8-2.8, P = 0.06). After 12 months, the healing rate of lymphocytic gastritis was significantly higher after triple therapy compared with omeprazole/placebo (intention-to-treat 95.8% vs. 53.8%, 95% CI for RR: 1.1-3.5, P = 0.01). All patients (n = 5) who received crossover triple therapy, showed healing of lymphocytic gastritis after further 12 months.CONCLUSION: Our study demonstrates that 1-week triple therapy aiming at eradication of H. pylori leads to a complete and long-lasting resolution of lymphocytic gastritis in the majority of patients.",
keywords = "Adult, Aged, Amoxicillin, Anti-Bacterial Agents, Anti-Ulcer Agents, Clarithromycin, Drug Therapy, Combination, Female, Gastritis, Helicobacter Infections, Helicobacter pylori, Humans, Lymphocyte Count, Lymphocytes, Male, Middle Aged, Omeprazole, Prospective Studies, Treatment Outcome, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",
author = "A Madisch and S Miehlke and F Neuber and A Morgner and E Kuhlisch and S Rappel and N Lehn and E Bayerd{\"o}rffer and G Seitz and M Stolte",
year = "2006",
month = feb,
day = "15",
doi = "10.1111/j.1365-2036.2006.02778.x",
language = "English",
volume = "23",
pages = "473--9",
journal = "ALIMENT PHARM THER",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial

AU - Madisch, A

AU - Miehlke, S

AU - Neuber, F

AU - Morgner, A

AU - Kuhlisch, E

AU - Rappel, S

AU - Lehn, N

AU - Bayerdörffer, E

AU - Seitz, G

AU - Stolte, M

PY - 2006/2/15

Y1 - 2006/2/15

N2 - BACKGROUND: An association between Helicobacter pylori infection and lymphocytic gastritis has been postulated.AIM: To assess the long-term effect of H. pylori eradication therapy on lymphocytic gastritis in a double-blind, placebo-controlled, multicentre trial.METHODS: Patients with lymphocytic gastritis were randomized to receive either 1-week triple therapy for eradication of H. pylori or omeprazole plus placebo. Endoscopy and histology was performed at baseline and after 3 and 12 months. Patients of the omeprazole/placebo group with persistent lymphocytic gastritis after 12 months received crossover open-label triple therapy.RESULTS: Fifty-one patients were randomized. Intention-to-treat analysis revealed a trend to a higher healing rate of lymphocytic gastritis 3 months after triple therapy compared with omeprazole/placebo (83.3% vs. 57.7%, 95% CI for RR: 0.8-2.8, P = 0.06). After 12 months, the healing rate of lymphocytic gastritis was significantly higher after triple therapy compared with omeprazole/placebo (intention-to-treat 95.8% vs. 53.8%, 95% CI for RR: 1.1-3.5, P = 0.01). All patients (n = 5) who received crossover triple therapy, showed healing of lymphocytic gastritis after further 12 months.CONCLUSION: Our study demonstrates that 1-week triple therapy aiming at eradication of H. pylori leads to a complete and long-lasting resolution of lymphocytic gastritis in the majority of patients.

AB - BACKGROUND: An association between Helicobacter pylori infection and lymphocytic gastritis has been postulated.AIM: To assess the long-term effect of H. pylori eradication therapy on lymphocytic gastritis in a double-blind, placebo-controlled, multicentre trial.METHODS: Patients with lymphocytic gastritis were randomized to receive either 1-week triple therapy for eradication of H. pylori or omeprazole plus placebo. Endoscopy and histology was performed at baseline and after 3 and 12 months. Patients of the omeprazole/placebo group with persistent lymphocytic gastritis after 12 months received crossover open-label triple therapy.RESULTS: Fifty-one patients were randomized. Intention-to-treat analysis revealed a trend to a higher healing rate of lymphocytic gastritis 3 months after triple therapy compared with omeprazole/placebo (83.3% vs. 57.7%, 95% CI for RR: 0.8-2.8, P = 0.06). After 12 months, the healing rate of lymphocytic gastritis was significantly higher after triple therapy compared with omeprazole/placebo (intention-to-treat 95.8% vs. 53.8%, 95% CI for RR: 1.1-3.5, P = 0.01). All patients (n = 5) who received crossover triple therapy, showed healing of lymphocytic gastritis after further 12 months.CONCLUSION: Our study demonstrates that 1-week triple therapy aiming at eradication of H. pylori leads to a complete and long-lasting resolution of lymphocytic gastritis in the majority of patients.

KW - Adult

KW - Aged

KW - Amoxicillin

KW - Anti-Bacterial Agents

KW - Anti-Ulcer Agents

KW - Clarithromycin

KW - Drug Therapy, Combination

KW - Female

KW - Gastritis

KW - Helicobacter Infections

KW - Helicobacter pylori

KW - Humans

KW - Lymphocyte Count

KW - Lymphocytes

KW - Male

KW - Middle Aged

KW - Omeprazole

KW - Prospective Studies

KW - Treatment Outcome

KW - Journal Article

KW - Multicenter Study

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/j.1365-2036.2006.02778.x

DO - 10.1111/j.1365-2036.2006.02778.x

M3 - SCORING: Journal article

C2 - 16441467

VL - 23

SP - 473

EP - 479

JO - ALIMENT PHARM THER

JF - ALIMENT PHARM THER

SN - 0269-2813

IS - 4

ER -